BTIG Research Issues Positive Forecast for MDxHealth (NASDAQ:MDXH) Stock Price

MDxHealth (NASDAQ:MDXH) had its price objective hoisted by research analysts at BTIG Research from $6.00 to $7.00 in a research report issued on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock. BTIG Research’s price target points to a potential upside of 66.07% from the company’s previous close.

Several other research firms have also recently commented on MDXH. Wall Street Zen upgraded MDxHealth to a “hold” rating in a research note on Saturday, August 30th. Weiss Ratings restated a “sell (e+)” rating on shares of MDxHealth in a report on Wednesday, October 8th. Finally, Craig Hallum began coverage on shares of MDxHealth in a research report on Thursday, July 17th. They set a “buy” rating and a $8.00 price target for the company. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $7.50.

MDxHealth Trading Up 2.3%

Shares of MDXH traded up $0.10 during mid-day trading on Thursday, hitting $4.22. The company had a trading volume of 96,244 shares, compared to its average volume of 119,569. MDxHealth has a 1-year low of $1.35 and a 1-year high of $5.33. The business’s 50-day simple moving average is $4.31 and its 200-day simple moving average is $3.04. The stock has a market cap of $199.32 million, a PE ratio of -4.79 and a beta of 1.68. The company has a quick ratio of 1.22, a current ratio of 1.31 and a debt-to-equity ratio of 13.81.

MDxHealth (NASDAQ:MDXH) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.04). The company had revenue of $27.43 million for the quarter, compared to analyst estimates of $24.11 million. MDxHealth had a negative return on equity of 374.98% and a negative net margin of 34.98%. MDxHealth has set its FY 2025 guidance at EPS. Sell-side analysts forecast that MDxHealth will post -1.15 earnings per share for the current year.

Hedge Funds Weigh In On MDxHealth

A number of hedge funds have recently modified their holdings of the stock. Russell Investments Group Ltd. purchased a new position in MDxHealth during the 3rd quarter worth approximately $461,000. Jefferies Financial Group Inc. purchased a new position in shares of MDxHealth during the third quarter valued at $53,000. GSA Capital Partners LLP acquired a new position in MDxHealth during the third quarter valued at $48,000. Calamos Advisors LLC purchased a new stake in MDxHealth in the 3rd quarter worth about $305,000. Finally, FreeGulliver LLC purchased a new position in MDxHealth during the 2nd quarter valued at about $273,000.

MDxHealth Company Profile

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.